The Ethics of Gene Editing
Few technological advances have provoked so vexed a moral reckoning as the advent of precise gene-editing tools. The capacity to rewrite the human genome with comparative ease confronts us with possibilities that were, until recently, the province of speculative fiction. Germline editing — alterations that would be inherited by all subsequent generations — sits at the contested heart of the dispute, for it implicates not merely the individuals treated but their descendants, who can offer no consent.
Proponents frame the matter in the language of compassion. To withhold a technology capable of expunging hereditary diseases, they argue, is itself an ethical failing, a refusal to relieve suffering that we have the means to prevent. From this vantage, hesitation is not prudence but a kind of complicity in avoidable harm. The moral burden, they insist, falls on those who would delay.
Sceptics counter that the very precision of the rhetoric obscures a thicket of uncertainties. Our grasp of the genome remains partial; interventions presumed benign may carry consequences that surface only generations hence. Moreover, the line between therapy and enhancement is notoriously porous. A technique sanctioned to forestall disease may, by imperceptible degrees, drift toward the engineering of preferred traits, with all the troubling questions of equity and coercion that such a drift entails.
There is, too, a deeper unease that resists tidy articulation. Some commentators speak of a wisdom in restraint, a recognition that certain powers, however benevolent in intent, exceed our capacity to wield responsibly. This intuition is easily caricatured as mere technophobia, yet it gestures at a serious point: that the irreversibility of germline changes demands a humility commensurate with the stakes.
No consensus has emerged, nor is one imminent. What the controversy lays bare is less a disagreement about facts than a divergence in how we weigh competing goods — the relief of suffering against the integrity of an inheritance we did not author and cannot fully foresee.
Прочитайте текст і виконайте завдання.
- 1
Why does the passage single out germline editing as especially contentious?
- 2
What is the rhetorical effect of the proponents framing delay as 'complicity in avoidable harm'?
- 3
In context, the phrase 'the line between therapy and enhancement is notoriously porous' suggests that:
- 4
The passage treats the intuition favouring restraint as nothing more than irrational technophobia.
- 5
The author concludes that the core of the controversy is a clash of values rather than a dispute over facts.
- 6
Which concerns are raised by the sceptics in the passage? (Choose all that apply.)
Оберіть усі правильні варіанти.
Що у цьому завданні (1)
- Editing the Human Inheritance — Прочитайте текст і виконайте завдання. · Few technological advances have provoked so vexed a moral reckoning as the advent of precise gene-editing tools. The capacity to rewrite the human genome with comparative ease confronts us with possibilities that were, until recently, the province of speculative fiction. **Germline editing** — alterations that would be inherited by all subsequent generations — sits at the contested heart of the dispute, for it implicates not merely the individuals treated but their descendants, who can offer no consent. Proponents frame the matter in the language of compassion. To withhold a technology capable of expunging hereditary diseases, they argue, is itself an ethical failing, a refusal to relieve suffering that we have the means to prevent. From this vantage, hesitation is not prudence but a kind of complicity in avoidable harm. The moral burden, they insist, falls on those who would delay. Sceptics counter that the very precision of the rhetoric obscures a thicket of uncertainties. Our grasp of the genome remains partial; interventions presumed benign may carry consequences that surface only generations hence. Moreover, the line between therapy and enhancement is notoriously porous. A technique sanctioned to forestall disease may, by imperceptible degrees, drift toward the engineering of preferred traits, with all the troubling questions of equity and coercion that such a drift entails. There is, too, a deeper unease that resists tidy articulation. Some commentators speak of a wisdom in restraint, a recognition that certain powers, however benevolent in intent, exceed our capacity to wield responsibly. This intuition is easily caricatured as mere technophobia, yet it gestures at a serious point: that the irreversibility of germline changes demands a humility commensurate with the stakes. No consensus has emerged, nor is one imminent. What the controversy lays bare is less a disagreement about facts than a divergence in how we weigh competing goods — the relief of suffering against the integrity of an inheritance we did not author and cannot fully foresee.